Pod Insights Pharmacy Podcast Network Advocating for LTC Pharmacy: Policy Battles & Industry Shifts | FrameworkFocus™ About this episode The political landscape is shifting, and long-term care (LTC) pharmacies are feeling the impact. In this episode of FrameworkFocus, we sit down with Alan Rosenbloom, President & CEO of the Senior Care Pharmacy Coalition, to discuss the key policy challenges facing LTC pharmacies in 2025. From the effects of the Inflation Reduction Act and ongoing PBM reform efforts to the push for LTC at Home and the looming threat of NADAC payment changes, Alan breaks down what’s happening in Washington and what it means for LTC pharmacies nationwide. Tune in for expert insights on the regulatory road ahead and how the industry can advocate for meaningful change.
Transcript 0:05 Speaker 00 You are listening to the global network of podcasters dedicated to the pharmacy profession. Welcome to the pharmacy podcast network.
0:31 Speaker 01 You're listening to Framework Focus, the podcast that explores trends, innovations, and insights in the long-term care pharmacy industry. Join us as we connect the entire LTC ecosystem.
0:44 Speaker 02 Hello, welcome to the 21st episode of Framework Focus, a podcast where we explore the latest innovations, challenges, policy shifts shaping the long-term care pharmacy industry. I'm Scott Beatty, and today we're diving into a crucial discussion on advocacy, policy battles, and the evolving landscape of LTC pharmacy. I'm thrilled to be joined by a true expert in the field, Alan Rosenbloom, President and CEO of the Senior Care Pharmacy Coalition. Alan has been a leading voice for the independent LTC pharmacy community, working on the front lines to navigate complex regulatory and legislative landscapes while ensuring patients receive the care they need. Today's conversation, we're going to explore the most pressing policy issues facing LTC
1:29 Speaker 02 pharmacy today. We'll also take a look at broader industry shifts and discuss reimbursement challenges and other issues facing our pharmacies. There's a lot to cover, let's jump in. Alan, first, welcome to Framework Focus.
1:43 Speaker 03 Thanks, Scott. It's a real pleasure to join you. I always appreciate the opportunity to talk with you, support Soft Riders and its work. And, you know, as you know, a lot of our members are your customers. I'm sure you'd like more. And so I'm glad I can be helpful and hopefully spread the word on some of the challenges we face in Washington and ways that pharmacies and others can get involved in helping us solve those problems.
2:10 Speaker 02 Absolutely. So Alan, I met you for the first time at our Soft Riders User Conference in 2016. You were asked to speak at that conference. You led a passionate discussion about the political landscape at that point in time. And boy, doesn't that seem like a lifetime ago, 2016, political landscape.
2:28 Speaker 03 Several, yeah, several lifetimes ago.
2:31 Speaker 02 It was a little simpler.
2:32 Speaker 03 Yeah.
2:34 Speaker 02 So let's start with a brief introduction. If you wouldn't mind, could you just give us a little overview of SCPC? And your organization's overall mission?
2:43 Speaker 03 Sure. The Senior Care Pharmacy Coalition exists to defend the public policy interests of long-term care pharmacies in Washington at the federal level. And we are focused on pharmacies as business operations and dealing with the issues that they face in the marketplace as they inflect with respect to federal policy. A lot of this work pertains to Medicare Part D, primarily in the Part D space, payment issues. To a lesser extent, we will become involved in payment issues associated with Medicaid, TRICARE, federal employee health benefits and so on. But as you know, 75% of long-term care pharmacy revenues come from Medicare Part D.
3:25 Speaker 03 So that's the heart and soul of that aspect of our work. Occasionally, issues come up with respect to oversight in the FDA, but those are much less frequent and much less, have much less immediacy in terms of importance for long-term care pharmacies. And, you know, we started, as you said, we met in 2016. The organization was founded in 2014. So we're in our 10th, 11th year now, which is hard to believe. And we've, you know, we've grown pretty substantially. We've, our membership, pharmacy membership has increased between 10 and 11 fold over 10 years. Our revenues have increased between five and six fold over that same period of time.
4:07 Speaker 03 We've grown a substantial business partner, membership to support us as well, including Soft Riders. And that, that is essential to our, you know, our success for. Hopefully, success in Washington. So that's kind of what we do. And we try to make sure that our members are not only fully informed and up to date on what we are doing to try to help them, but also make sure that they have opportunities to participate and help us understand what they do, translate it into the policy world, and try to seek solutions that work for them.
4:43 Speaker 02 Great. So, perfect segue into, why don't you give us a little snapshot into the key priorities for SCPC in the year ahead?
4:51 Speaker 03 Sure. Number one priority is dealing with a huge problem that is being created by the negotiated drug prices under Medicare. In, you know, 20, I guess it was 2022, Congress passed the Inflation Reduction Act. It had a whole bunch of different things. Part of that was to empower CMS to negotiate prices for the most expensive brand name drugs. And that's essentially the drugs that cost the federal government the most. And for the first two years of this program, 2026 and 2027, this only applies to Part D drugs. D is in David, which is, of course, the centerpiece of the long-term care pharmacy business. And when you look at the drugs that are on that list, there are
5:36 Speaker 03 10 drugs in the first year, about eight of them are very heavily prescribed to long-term care patient population, and are a substantial chunk of both revenues and margin for long-term care pharmacies. As you know, long-term care pharmacies, about 90% of the drugs that they dispense are generics, about 10% are brands. The generics are around break even. It kind of depends on how well you purchase and what your contracts are, as to whether you do a little bit better than break even, or a little bit worse than break even on ingredient costs. But you don't run your business on the margin that you get from brands either way. You know, dispensing fees are way lower than costs. Last year, we commissioned Clifford Larson Allen
6:20 Speaker 03 to do a study of what it actually costs to meet the requirements that are imposed on long-term care pharmacies. And it averages about $15 a prescription. Doesn't matter, of course, whether it's generic or brand. That's what it costs. Part D plans on average pay about $4. So every time a prescription's dispensed, you're losing $11 as compared to your costs to dispense. So you make it up on brand margin. And with the MFP or negotiated price, maximum fair price, these are the negotiated, that's the term of art for the negotiated prices. With those negotiated prices, which is the most that a part D plan can pay for ingredient cost reimbursement,
6:59 Speaker 03 it kind of eviscerates the market. You know, we estimate that, you know, for the average long-term care pharmacy operating margin, that is EBITDA effectively, is going to be 30% lower. And that's obviously before you do capital, you know, capex reinvestment, before you invest in growth, before you pay your taxes, before you do your debt service, and before you're hopefully left with something at the end of all of that. That's a pretty devastating loss for long-term care pharmacies. And, you know, coming right on the heels of that, or that now we know what the 15 drugs that have been announced for 2027 are. We don't know what the negotiated prices are, but those are also very heavily prescribed, 10 of them in long-term care.
7:43 Speaker 03 And we estimate that the impact of that ballpark, because we don't know exactly until we know the prices, is going to be up about 40% of the impact in 2026. So you're looking at, you know, a 30% margin hit in the first year and a 10% to 12% margin hit in the next year. That's devastating for this sector. And so that is our primary focus.
8:09 Speaker 02 And talk a little bit about how the new presidential administration impacts this inflationary reduction act or just broader pharmacy policy as you see it. How does that differ from the previous administration?
8:23 Speaker 03 To be honest, we don't know yet.
8:26 Speaker 03 You know, a lot of the focus of the Trump administration and the Republican Congress right now is on extending and making permanent tax cuts from 2017, which will cost a lot of money. And so the focus is more on where do we cut across a whole spectrum while protecting Medicare. You know, President made a, made a promise that this wouldn't affect Medicare and Congress is trying to keep that promise. We'll see if it actually works out. In terms of healthcare policy that is just at the administrative level, there are just hints because it's clear the administration's focus is elsewhere. So RFK Junior in his confirmation hearings essentially said that they plan to continue
9:11 Speaker 03 the IRA drug price negotiation program as is. They may have some little tweaks behind the scenes. Having said that, there's a lot going on in this space because putting aside this long-term care pharmacy specific issue that I've described, there is, there are a whole bunch of implementation problems and costs that pharmacies are going to have to bear as a result, which is occupying a lot of oxygen to see whether or not, and the pharmacy space, see whether or not the administration or CMS could do something a little bit differently in terms of implementation to improve the situation. There are some calls to delay implementation. And as you, as you may have seen in recent days,
9:54 Speaker 03 pharma, pharma executives met with the president and our understanding of what they want with respect to the IRA is some changes in some of those internal decisions that the administration can make, which would mean effectively that drugs would be, that, you know, high, high profit drugs would somehow get delayed in getting on the negotiation. ...price, you know, schedule, rather than stopping the thing or trying to reverse the thing. And the problem with any effort to stop it or repeal it is that it costs a lot of money from the federal budget perspective, which makes it difficult. And that's not what they're focused on. So you can probably tell that just from the news media reports that healthcare is not at the
10:39 Speaker 03 top of the agenda. Now, you will hear references to the IRA, but the IRA had a whole bunch of other stuff in it. It wasn't just the Medicare drug pricing provisions and the restructuring of Part D. It was also climate, you know, you know, climate change policies and other kinds of policies that the Republicans are anxious to repeal. But there's not, there's no talk at all about trying to deal with, with, you know, the IRA drug pricing provisions at this point, at least in terms of big picture policy change.
11:14 Speaker 02 Understood. And just to give the group or listeners a bit of a better perspective, I know from participating in SCPC, you have deep relationships across both sides of the aisle. And your advocacy efforts are pretty wide reaching across, you know, the Congress and multiple members of different healthcare committees. Can you just talk a little bit about that so that the audience understands your focus is not just a small group of people that just changed out as it relates to the presidential administration?
11:44 Speaker 03 Yeah, you know, I'd be happy to do that. And I appreciate the opportunity because if you are, you know, in the Washington environment, if you're trying to drive policy changes, which is of course, what we're trying to do, you have to be good at a series of things. One of the things you need to be good at is lobbying. It is directly talking to members of Congress about the issues of the issues that are of concern to you and persuade them that What you're trying to accomplish is what they ought to try to support, right? For example, I mentioned this drug pricing situation and because of all of the political dynamics, you know, the, the need to reduce spending in certain arenas, the fact that our proposal is going to cost a little bit of money, however you do it, and trying to figure that out.
12:29 Speaker 03 We've decided that, that, you know, this year's strategy is live to fight another day. So we're trying to get a two-year solution, which for the drugs that are subject to negotiated prices would mean that pharmacies, long-term care pharmacies, will get an additional supply fee over and above whatever the negotiated dispensing fee is and whatever the negotiated ingredient cost reimbursement is. And we calculated that based on what we think if you take all the risks into account that we bear and have no control over, uh, we, the amount that we think would fill that hole. And that will allow us a little bit of breathing space to deal with a longer-term solution
13:12 Speaker 03 that is, is more sensible than just keeping, you know, keeping what band is on the system. So I provide that as context because now let's talk about what you asked, which is political relationships. How do we do that? We have to look at the political reality today, which is of course the Republicans control every chamber, both the Senate and the House. They've got the White House, but as you can see, the Republicans are not unified. You know, uh, they want to do what's known as reconciliation and reconciliation is basically a technique that gets around the fact that most things in the Senate have to pass by 60 votes.
13:49 Speaker 03 Right? Because there are 53 Republicans and that would mean that whatever gets considered and passed would have to have at least seven Democrats voting for it. And many of the things, especially the extension of these, these tax cuts that the Republicans would like to see, the Democrats are just never going to vote for, right? Plus, Because of the way President Trump is acting unilaterally, whatever you think of that, the Democrats are less and less and less and less and less likely to cooperate because they feel that the president is overreaching and exceeding his congressional, his constitutional authority. And frankly, behind the scenes, there's some Republicans who agree, but are not going to say that publicly.
14:32 Speaker 03 So in that environment, what do we do? Oh, the one thing I also want to mention about reconciliation is that the trick about reconciliation is that it only applies to the budgetary process. So anything that gets into a reconciliation bill, theoretically at least, has to be driven by, you know, impact on the budget rather than by the policy objectives. That is honored in the breach in very significant measures, but parliamentarian of the Senate gets to decide. And you can expect that the Democrats, if they don't like policies that are in this reconciliation bill or package or whatever they come up with, will be challenging all of those and there will be parliamentarian rulings that could kick things out. So that's kind of the dynamic.
15:15 Speaker 03 So our first cut opportunity to get our solution is to try to get it into reconciliation, which is of course all Republicans because frankly, no Democrat is going to vote for reconciliation. And in order to do that, we've got to have relationships with members of Congress at the, at the kind of, you know, rank and file level. People who are on committees but are not in leadership of committees or not in overall leadership. And we have, you know, we have those kinds of relationships. There are people like on the, on the Republican side of the aisle, Morgan Griffith from Virginia, Diana Harshberger from Tennessee, Adrian Smith from, from Nebraska and so on. On the Democratic side of the aisle, Brad Schneider from Illinois, you know, and a
16:00 Speaker 03 few others. I'm just giving these as examples to, you know, say, rank and file, we've got to have relationships there. We have relationships at the lobbying level. We also have relationships at the grassroots level because, you know, elected officials care about a couple of things, but the things they care about the most are Am I going to get reelected? So votes. And do I have enough money to run my campaign? So political contributions. And I mentioned that there are four or five domains that you have to be good at. One of them is the lobbying, and that is at the grassroots, at the rank and file level. That's at the committee leadership level. So the committee that has primary jurisdiction over Medicare Part D is the Energy and Commerce Committee. The chairman is Brett Guthrie from Kentucky.
16:44 Speaker 03 He's somebody we have a very good relationship with. And the Health Subcommittee and the chair there is Representative Buddy Carter from Georgia. Pharmacist, former long-term care pharmacy owner. Many, many people who will be listening to this probably know him personally. And he is a real ally for us. So that's kind of the way we work relationships. And then, of course, leadership. Speaker Johnson is primarily the person we need to deal with. And we are, in fact, we have a series of meetings in a couple of weeks, including a, you know, a sit down with the speaker to try to explain this in more detail. We've talked to him about it a few times and hopefully get his commitment to help us fix the problem. So that's, that's domain number one. I'll stop there because I could talk about the other domains because they're complementary.
17:29 Speaker 03 But I don't know if you want me to go there now. You want to head in a different direction.
17:32 Speaker 02 No, I think that's great. Look, it's, it's important, I think, for our listeners to understand the breadth and the depth of the work that you do at SCPC as it relates to this advocacy work because it takes years to build and sustain these relationships. And you obviously have situations where there's turnover in certain seats. And, and so your, your efforts ensure that the continuity of the progress you're making in the advocacy work doesn't stop with a few seats changing, right?
18:01 Speaker 03 Yeah, yeah, it's not just, it's not just members of Congress changing. It's the staff changing because most of the work you do is actually with staff. You know, and you develop these relationships and folks move around. So over time, that helps. But in the short term, yeah, it's a constant re-education process. Most people on the Hill, when we started, and this is one of the reasons that SCPC started, there was one, and I, I mean this sincerely, one member of Congress who understood long-term care pharmacy, understood that it was different from retail pharmacy. And that was Buddy Carter. And at the time, most people did not know what a PBM was. I mean, members of Congress. Right? So part of, part of our mission was to help the fight on PBMs. And an important part of our mission was getting people to understand what long-term care pharmacies are,
18:45 Speaker 03 how they differ, and why policies need to be inflected differently to make sense for us. And now, a lot more people know what long-term care pharmacy is, and understand that there needs to be these, there need to be these kind of policy inflections. And some of the PBM reform legislation that is pending reflects those, reflects that success. We got a long way to go. And so to come back, I talked about the direct lobbying. That's me and our, we have a very strong group of contract lobbyists. One of our two, one or two of our members have internal corporate lobbyists and we coordinate that. We also, to the extent we can, partner with other organizations that are, that have, that are like-minded
19:28 Speaker 03 in terms of their objectives. We have a grassroots program. And this is where, you know, pharmacies can really be helpful and pharmacists can really be helpful. Because the more we can connect the dots to people who are in the communities that the members of Congress serve, the more likely we are to be able to leverage the combination of what we're doing in Washington and that, and some other things. And, and those, those local relationships to, to drive policy change. And that's kind of a challenge for long-term care pharmacies because, you know, there's not a long-term care pharmacy in every congressional district in the country. But people who need long-term care are being served by long-term care pharmacies
20:12 Speaker 03 in every congressional district in the country. And so, you know, this grassroots stuff builds over time and becomes part of the, part of the equation. It's important to have facts. In Washington, everybody has, has, you know, analytics and so on. And that's a big part of what we do is to make sure that we have the research capacity through third-party relationships to make the kind of statements I made today. And this, you know, in this conversation, like the fact that the impact of the negotiated price drugs in 2026 will, you know, on average, mean 30% reduction in operating margins. Right? Because when I go in to talk to a member of Congress, we have credible data that says that.
20:55 Speaker 03 The final, there are two other pieces of the puzzle. I'll just mention them quickly. One is communications. You've got to be able to get your message out and we have a a pretty good function there. We'd like to strengthen that, to be honest, and we're in the process of doing that. And then finally, unfortunately, political action. I mentioned money earlier. Members of Congress respond and sometimes the easiest way to tee up an issue is at a fundraiser. Now, you don't get, you know, it's not like a quid pro quo. It's not like you contribute and you get what you want, but it does give you a forum to just talk about one issue for an extended period of time with a member of Congress and then feed that back into the whole process. Meeting with the staff, building from the
21:39 Speaker 03 staff to other members of Congress, getting grasp, getting, you know, constituents to say, this is a problem. Can you help us fix it? And then, you know, kind of coordinating all of that into a dedicated campaign, which is what we are doing right now on this, on this drug pricing issue in particular.
21:57 Speaker 02 Right. So as you talk about the successive grassroots efforts and communications required, a big part of that is demystifying a really complex set of circumstances, right? The second and third order effects, unintended consequences of the legislative actions. And so can you just talk a little bit about the Save Senior Care R X and just what that's attempting to do? And then I do want to talk about PBMs, which is, you said that's where the organization started and we're still very much fighting that battle. So I want to dig into that.
22:25 Speaker 03 Absolutely. Yeah. Yeah. So, so the Save Senior R X campaign, we launched last summer because of this drug pricing issue and because we were hoping that other organizations would join us in this fight. And that was the vehicle for, for, for, you know, kind of allowing people to participate without necessarily being SCPC members.
22:51 Speaker 03 And now that we and we're now actually next week, there's going to be a meeting in DC to try to really get some partners active in that campaign and supportive of the campaign, which is designed to get the same solution that I've already described, but to but to be a forum for a coalition to help support it. Right. And that's what that's what the campaign's about, whether it's through SEPC directly, just uniquely on behalf of long-term care pharmacies in our membership, or, you know, this broader group that we hope will have, you know, advocacy groups for patients and for for people who need long-term care, other pharmacy groups, facility-based groups like the American Healthcare Association, which has been a very good partner for us.
23:36 Speaker 03 And you talk about second second order effects and third order effects. You know, one of the if this problem doesn't get fixed, of course, long-term care pharmacies face a very, very, very difficult economic situation. For everybody, it's a material, it's a material risk. For smaller pharmacies or companies that have pharmacies in rural areas, it's an existential risk. You know, and I really don't see how small pharmacies serving rural facilities survive. And I don't see companies that have multiple pharmacies, but that have pharmacies in rural areas will keep those open. So what are the second order effects? Those, you know, if they're if they're skilled nursing facilities, they can't get their drugs from a retail pharmacy.
24:21 Speaker 03 The residents can't get their drugs from mail order. That pharmacy, that facility closes. Period. It closes. Now, that's not going to be a huge, it's not going to be 20% of the sector, but it's some some subset of the sector is going to have that kind of problem. For the rest of the facilities, pharmacies are going to need need more on the par day side. And we estimate that at minimum, it's a 25% increase in facility drug spend.
24:46 Speaker 03 From part A, which facilities are not thrilled about, right? So we're hoping that they will partner with us because of that. Similarly, for patients, access will diminish those rural areas, for example, and services will either become à la carte or less frequent. So there'll be less frequent deliveries, you know, and so forth. And that can lead to, you know, patient, patients not getting the drugs when they need them, drug complications that could have been avoided, unnecessary hospitalizations, et cetera.
25:16 Speaker 02 And when you talk about even a small percentage of facilities closing, when you look at the demographics and the increasing patient populations that need to be served through long-term care, even a small percentage of facility closures would be a significant issue.
25:32 Speaker 03 Yeah, I think so. It depends on the area, right? Because, you know, if you look at on the facility side, right? Before COVID, occupancy was in the low 80%. And that was, you know, for some that was break even. For some it was, it was, you know, they were, they were doing, you know, better. COVID devastated facilities. The occupancy has been slow to come back up, primarily, I think, due to staffing problems. Can't get the staff, so you can't fill the beds. And, and it seems to be back kind of to a reasonable level now. So while there is capacity, there are some areas where there is no capacity. And that's where you're going to have these problems.
26:16 Speaker 02 So ultimately, what we're talking about is, is underlying financial hardship created by some of these programs, legislative evolutions, as well as the PBMs. So let's, let's dig into that a little bit. I want to sort of hear from you, you know, this is a really core issue. And so can you just talk a little bit about how PBMs are impacting LTC pharmacies? And what reforms are currently being evaluated or proposed at the federal level?
26:44 Speaker 03 Sure, sure. Well, you know, at
26:49 Speaker 03 PBMs impact long-term care pharmacies in ways that are similar to all pharmacies. So it's a constant financial squeeze, essentially, right? Always downward pressure on payments, downward pressure on dispensing fees, downward pressure on ingredient cost reimbursement, both on the generic side and the brand side. And then all of the additional fees that come up that you get charged, not just simple switch fees or transaction fees, which it's reasonable that a PBM gets a flat transaction fee for processing a claim. That was the original idea.
27:29 Speaker 03 But because of the ability to control formularies, that's created the power, if you will, that PBMs wield. And then that's why they consolidated. That's why they became part of mega corporations like CBS and United and ESI, Cigna and so on. And so the disproportionate market power just continues to, it's like a balloon, right? Squeeze the balloon. So you get a look like, one of the other reasons SEPC formed is that there were no GERS on generics at the time that SEPC came together.
28:11 Speaker 03 And the generic rate was just plummeting. Ninety percent of scripts are generic and long-term care pharmacies needed separate representation to deal with that. We got some things done in Washington that I think helped the PSAOs negotiate contracts that had GERS in them. Well, over time, the GERS have eroded. The PBMs are not reconciling fairly at the end of the year to actually get to the GERS. And so that's one of the, I think, one of the pressure points, right? Going forward, one of the concerns is what happens with the MFP, the negotiated prices? Because...
28:53 Speaker 03 The negotiated prices also mean reduced rebates for PBMs and plans. So their economics change. When their economics change, how does that filter down to long-term care pharmacies? And, you know, the contract negotiations for 2026 are kind of already underway. For some of the bigger companies, they're probably close to resolution for the PSAOs. And the smaller companies or mid-sized companies that negotiate through them, it's going to take a little longer to get the contracts done. But, you know, the plans are saying, we're going to look, we're going to lose big rebate dollars in 2026, even though they will try to manipulate the formularies, you know, to shift. That's not always going to be possible.
29:35 Speaker 03 And so is that, how is that going to put pressure on the long-term care pharmacies? Because remember, the ingredient cost reimbursement for those negotiated-priced drugs has a ceiling, but not a floor. Plans can't pay more than the negotiated price, but they can pay less. And we don't know yet whether that will be a pressure point. Will they try to put more pressure on dispensing fees? I do think one of the things you're seeing is that plans are less willing, and PBMs are less willing, to pay higher dispensing fees for long-term care pharmacy services in settings outside skilled nursing.
30:16 Speaker 03 So in assisted living and in the community, you know, it used to be that in assisted living, you'd get a higher dispensing fee, although it wouldn't be the sniff dispensing fee. And to some degree, you might get a little bit more in community. I think that plans are simply moving away from that because they don't legally have to do that. So why wouldn't they? Right? It's money in their pockets or in long-term care pharmacies' pockets. And if their economics are going south, they're going to pass it along. They're going to pass the pain along. So that, I think, is our biggest immediate PBM concern, as well as all of the things that have been out there forever. The abusive practices, the predatory audits, you know, the overall predatory behavior, the, you know, the...
30:57 Speaker 03 Failure to meet contractual terms and basically say sue us because they've got much deeper pockets than than we do. All of those things are out there. So how does that play into the pending legislation? And as you probably know, last year, there was a kind of a deal at the end of the year to for Congress to get out of town. It included PBM reform in it. Elon Musk blew that up. You know, he complained about the debt ceiling and then President Trump or then President-elect Trump jumped on the bandwagon. House Republicans, you know, cowered in fear. Suddenly, the plan blew up. The second plan blew up. And
31:38 Speaker 03 ultimately, the PBM reform stuff got dropped off the table. There is a lot of pressure to get it back on the table and into something this year. Probably not the reconciliation package, although it's possible because it saves money. But maybe something at the end of the year. And Buddy Carter, who I mentioned, Brett Guthrie, Jamie Comer is a House member from Kentucky, Chair of the Oversight Committee. These are relatively powerful folks who really want to get this done and are doing things in Washington to try to get it done. So let's talk about what's in that package because it's probably going to be what was in the year end package last year. And I think there's going to be a lot of ads. And that itself was a compromise between the Senate and the House that kind
32:22 Speaker 03 of took out some very good provisions with respect to Part D. And so on the Part D side, I would say that what they're what they're that package contained was kind of, you know, B minus reforms, B minus, C plus. It was a lot of disclosure, but a lot of the disclosure ran from the PBMs to the plans, which is kind of like talking to yourself in most cases. So it wasn't clear that that how that was going to make a lot of change. But so on Part D, you know, it was kind of Like I said, B minus. On Medicaid, however, even though that's only a small percentage of our business, there was something in there that would be very valuable.
33:05 Speaker 03 And essentially, it would have required that Medicaid managed care pay the same dispensing fees as Medicaid fee for service. And to give you an example, in the retail context, the average Medicare dispensing, Medicaid dispensing fee on the fee for service side, this is for everybody, you know, because the way they do it, so this is long-term care and retail, was about $10.50. The average dispensing fee in, actually, just right before this call, right before we started talking, I was in a discussion with our analysts on what Medicaid managed care dispensing fees look like for long-term care pharmacies. And it's a wild range.
33:48 Speaker 03 It ranges from 27 cents to $11.94, depending on the state and the program. And the higher states, the higher one, that $11.94, is in a state where the state requires the same dispensing fees. So what this legislation would do is take that and make it federal, so all across America. And that would be a huge increase in dispensing fees. So that'd be a big win on the Medicaid side. Small part of the business for long-term care pharmacies, but a big win. In the commercial space, that was really the sticking point. The commercial stuff is more disclosure oriented and it runs to, you know, PBM's disclosing to employers, which seems reasonable and, you know, that seems like a good thing, but not particularly relevant to us.
34:33 Speaker 03 So there's a long way to go on PBM reform beyond that. I do want to mention that one of the pieces of legislation that I'm not sure survived into the ultimate package took something that already exists. Right now, the Part D statute guidance regulations have this thing called the "any willing provider" provision, which means that any pharmacy that is willing to accept the basic contract the plan is offering has to be allowed into the network. But those contracts generally are terrible. And CMS historically has said, "Well, if a pharmacy accepts a contract, then it must be reasonable." Which is, of course, ridiculous if you understand the market dynamics.
35:17 Speaker 03 Sometimes you have no choice. You either participate and lose money, but keep the business of your retail pharmacy on the front end of the store, or you can't survive. So Congress, in this legislation, would have given some teeth to that provision.
35:35 Speaker 03 Right? And would have required actual regulatory standards on what it meant to have reasonable and relevant contract terms. Congress, so that was one thing. But interestingly, and I think in part because of all of this, when CMS published the regulation this year for the 2026, it's called the payment rule, but basically every year they tell the plans what they're going to do differently. You know, and it's a regulation, subject to public comment, et cetera. And it also has provisions that are relevant to us. One of the things they asked is for input, it was kind of a request for information, input on how they should go about giving teeth to this provision that already exists. Right?
36:18 Speaker 03 And the term of art is reasonable and relevant contract terms. So what should they consider? And what we did is, we had like a 20-page submission where we listed all of these abuses that our members had identified, categorized them, and made suggestions about how to create reasonable and relevant contract terms that prevent these kinds of abusive practices from happening. And we are now working with Mr. Carter, who I mentioned, there there's in Congress, to put pressure on CMS to now publish regulations that speak, you know, proposed regulations for public comment that try to define those contract terms. So that, I think, has some real promise for us, because that's all part D.
37:01 Speaker 03 Long way to go, but I think real progress.
37:05 Speaker 02 So what actions can LTC pharmacies take to advocate for meaningful PDN reform?
37:13 Speaker 03 Right now?
37:14 Speaker 02 Yeah.
37:14 Speaker 03 Uh, I think, I think the thing to do is to contact your members of Congress and we can help you do that if you're members and even if you're not, talk to me. Um, you know, to say, we need PBM reform, we need this stuff right now and we need more and it needs, and we need some long-term care pharmacy specific reforms because some of these issues inflect differently for us than they do for retail. For example, this reasonable and relevant contract terms. Well, because we have, because there's a separate long-term care pharmacy network advocacy requirements, you know, contract terms are different. That's, that is why there's a higher dispensing fee in skilled nursing facilities than there is in retail because of that provision.
37:57 Speaker 03 So how do we make sure that these reasonable and relevant contract terms take that into account? We obviously argued for that in our comments. We tried to get that provision changed, but unsuccessfully. And because, because basically CMS said, we have, you know, we, we would be able to do that anyway and we can exercise discretion to do it. But I'd rather have Congress tell them to do it than fight with CMS about it.
38:21 Speaker 02 Right.
38:21 Speaker 03 So, so really what you can do is you can get involved. That's, that's the bottom line. Get involved. In the ideal world, you join SEPC if you're not already a member, whether you are or you're not, you'd find ways to engage with your members of Congress, not only, you know, writing emails and that sort of stuff, but, but inviting them into your pharmacy, trying to get them to understand how long-term care pharmacy is different from retail pharmacy and why you need separate solutions and separate, and you know, and really get them aware, not only on the PBM side, but also on the, on the, you know, on the drug pricing side and set it up for the future.
38:56 Speaker 02 You've referenced a few times in this discussion, a few data elements, you know, specifically around the margin rates that will be eroded with some of the pending legislation or, or just current state of, of, of things with Inflation Reduction Act. How important is having quantifiable, you know, data elements as you're, as you're having that conversation with members of Congress and, and submitting your, your written responses and feedback? How important is that data to the success of your efforts?
39:27 Speaker 03 It's crucial. You know, in, in Washington, first of all, when you walk into a member of Congress's office, anecdotes are great, but to persuade policymakers and especially to persuade CMS, you need data. And if you have opponents, let's just say PBM opponents, right? Something beats nothing and they're going to have all sorts of analysis. You know, uh, and, and, and so it's important that you have it and it's important in my view that it be credible. A lot of the stuff that gets spewed out is not methodologically sound. It's not statistically relatively statistically, uh, you know, significant.
40:05 Speaker 03 And, um, it can eat in, and, and you will lose credibility, which is why we structure our data in, you know, with third party researchers.
40:16 Speaker 03 One of the challenges in the pharmacy space and the long-term care pharmacy space is there is limited publicly available data. There are some databases you can purchase and that's fine. We do, or, or, you know, consultants do. Uh, but a lot of what we do is gathering data from our members, which is a second reason why it's so important that we use third parties because we do not, we as SEPC do not want to know any details about individual members. We don't want to report based on individual member data. So we use third parties. The data doesn't go to us. It goes to them. We're prevented from seeing individual pharmacy information. It's only used in the aggregate. It's a little aside, but you need analytics. It needs to be sound and credible.
41:00 Speaker 03 And you need to be able to explain it if asked. And without data, it is very hard to drive policy in this arena.
41:08 Speaker 02 Right.
41:08 Speaker 03 You know?
41:09 Speaker 02 And the breadth and, and, you know, the, the level of commitment of, of your membership and of the broader LTC community will just improve the quality and, and impact that that data can have. You need more people involved. It's that simple.
41:23 Speaker 03 Absolutely. As you know, Scott, better than anybody probably listening to this. You know what it costs to do, to do data well?
41:32 Speaker 02 That's right.
41:32 Speaker 03 You know, it is not cheap, but it is, it is sufficiently valuable that it's worth it. And there, there is hu- huge ROI from investing in, in, uh, you know, good data systems and good data.
41:46 Speaker 02 Absolutely. It's a huge focus for soft writers in the year ahead, years ahead, I should say. So change gears a little bit. So we talked about some of the pressure on facilities. We know that there's been a not so recent trend of patients wanting to age at home. And so talk a little bit about there's the Alliance for LTC Pharmacy at Home. And how is that helping pharmacies? And can you just talk a little bit about that, the mandate there?
42:13 Speaker 03 Yeah, you know, the first thing I would say is that, you know, the next person I meet who wants to be in a long-term care facility will be the first person I have ever met who wants to be in a long-term care facility. You know, of course, you still need to have them. And like, if you just look at the Medicare population, there are a little over 4 million Medicare beneficiaries who need long-term care. Three quarters of them already live at home. Right? So there's this huge and growing population of folks who need long-term care, who are living at home or in the community and who want to stay there. Some will not be able to, but a lot will. And we, across the board, do not have an adequate service delivery system for them.
42:55 Speaker 03 In the long-term care pharmacy space, this is what the Alliance for Long-Term Care Pharmacy at Home is trying to do, is trying to improve access to long-term care pharmacy services at home. And effectively, what it comes down to, when you cut through all the rhetoric is, how do we make sure, how do we get long-term care pharmacies, or pharmacies that provide those services to people at home, to get paid for those services, or at least get paid the dispensing fee that long-term care pharmacies get in skilled nursing? And in order to understand what the Alliance is trying to do, you have to understand how that works. And essentially, it's not required. People think it is. CMS has created a series of incentives for plans to pay higher dispensing fees. They've created separate long-term care pharmacy network adequacy requirements,
43:40 Speaker 03 which enumerate the various characteristics that a pharmacy has to have to be included in proving to CMS that a plan has long-term care pharmacy network adequacy. These are the things that we're all familiar with. And that and a few other things. Kind of have have have have made PBMs and plans say, you know what? We need to pay higher dispensing fees because we don't want to get crosswise with CMS. If we don't have long-term care pharmacy network adequacy, we lose our our part decontract entirely. It's not just we lose the long-term care piece. And so we don't want to put ninety for ninety-five percent of our business at risk to get a few bucks on a dispensing fee for five percent of our business. But those requirements don't apply, don't extend to assisted living.
44:23 Speaker 03 They don't extend to to various congregate living settings, and they certainly don't extend to people at home. So the idea is to convince of the alliance is to convince CMS that they have the statutory authority to do more than they have already done to require plans to kind of behave as if this was a long-term care pharmacy network adequacy thing and to pay higher dispensing fees. Because if long-term care pharmacies were getting four or five bucks for for providing services at home instead of, you know, twenty-seven cents or thirty cents or a buck, then that would expand access. And frankly, if you expanded access at home, you would you would keep more people at home and you'd probably reduce overall healthcare spending.
45:06 Speaker 03 Right? Because if you look at it, people who are who need long-term care are taking, you know, twelve to fourteen prescriptions. And interestingly, in, you know, in in in SNFs, they're taking twelve. And assisted living, they're taking fourteen. And I my theory is that that's because there's less effective medication management and assisted living than there is in skilled nursing because of these requirements. So it's exploiting that kind of data, that kind of sensibility, and extending it to the at-home world as well as constructing legal bases on which CMS can say, you know what, we can tell plans to do more.
45:42 Speaker 02 Right, right. Well, I think we've just reached time, Alan. You probably need a drink of water because you just shared a whole host of really useful insights to us. Thank you very much. This was just such an insightful conversation. And it's it's very apparent that you have expertise across a wide range of issues. And and we really appreciate your advocacy and your leadership and in trying to drive, you know, the LTC industry into the future.
46:14 Speaker 03 Thank you, Scott. I appreciate that and I appreciate the opportunity to, you know, share some, share some thoughts with the soft writers constituency. And I, as always, it's a pleasure to spend an hour talking with you.
46:27 Speaker 02 Absolutely. So as we wrap up, I want to leave our listeners with, with a call to action. Whether you're an LTC pharmacy leader, a broader healthcare provider, or just an advocate for senior care, stay informed and engaged in these critical policy decisions that we discussed on, you know, today around the IRA, the PBM reform, the LTC to home alliance. And best way to do this would be to consider joining the Senior Care Pharmacy Coalition if you're not already a member. You can find more information on the website for that, for Senior Care Pharmacy Coalition or their LinkedIn page. We will drop in the show notes for today's discussion, the links to those locations. And of course, if you enjoyed this episode, don't forget to subscribe to Framework
47:12 Speaker 02 Focus. And thanks again for joining us. Thank you to our listeners. And really, Alan, from the bottom of my heart, I really appreciate your time today. Look forward to seeing you next month in Orlando at the SCPC meeting.
47:23 Speaker 03 Thanks very much. Take care, Scott.
Previous Sports Pharmacy: Play Ball! | Pain Pod Next ATRIUMX 2025 Press Coverage (Two-Part Series) | Part One Page updated November 15, 2026 · transcript and summary are machine-generated